The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8 + T cell activity and synergizes with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

The antibody‐based delivery of interleukin‐12 to solid tumors boosts NK and CD8 + T cell activity and synergizes with immune checkpoint inhibitors

Published:2019-08-28 Issue:9 Volume:146 Page:2518-2530
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Puca Emanuele¹^ORCID,Probst Philipp¹,Stringhini Marco¹,Murer Patrizia¹^ORCID,Pellegrini Giovanni²,Cazzamalli Samuele³^ORCID,Hutmacher Cornelia¹,Gouyou Baptiste³,Wulhfard Sarah³,Matasci Mattia³,Villa Alessandra³,Neri Dario¹^ORCID

Affiliation:

1. Department of Chemistry and Applied Biosciences Swiss Federal Institute of Technology (ETH Zürich) Zürich Switzerland

2. Laboratory for Animal Model Pathology Universität Zürich Zürich Switzerland

3. Philochem AG Otelfingen Switzerland

Funder

Eidgenössische Technische Hochschule Zürich

H2020 European Research Council

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32603

Reference63 articles.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

3. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

4. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

5. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tripokin: A multi‐specific immunocytokine for cancer immunotherapy;International Journal of Cancer;2024-08-23

2. Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy;OncoTargets and Therapy;2024-08

3. Cytokine Biopharmaceuticals with “Activity-on-Demand” for Cancer Therapy;Bioconjugate Chemistry;2024-06-17

4. A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors;EMBO Molecular Medicine;2024-03-06

5. XTX301, a tumor-activated Interleukin-12 has the potential to widen the therapeutic index of IL-12 treatment for solid tumors as evidenced by pre-clinical studies;Molecular Cancer Therapeutics;2023-11-30